Designation of Bortezomib (Velcade) as an Orphan Drug by Janssen-Cilag

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply of therapeutic goods in Australia, ensuring their quality, safety, and efficacy. The Act was introduced to address the need for comprehensive oversight of therapeutic products, aiming to protect public health by controlling the importation, manufacture, supply, and advertising of these goods. The Therapeutic Goods Administration, under the auspices of the Commonwealth of Australia's Department of Health, administers the Act. In the context of the 20 August 2014 designation of bortezomib (VELCADE) as an orphan drug for the treatment of patients with mantle cell lymphoma, the policy objective aligns with supporting the development of treatments for rare diseases, which often have limited market incentives for pharmaceutical companies to invest in, thereby ensuring that patients with rare conditions have access to necessary therapeutic options. This action underscores the legislative intent to foster innovation and access in medical treatments for underserved populations.

Scope and Application

The Therapeutic Goods Act 1989, as exemplified in the designation of bortezomib (VELCADE) as an orphan drug, applies to pharmaceutical products that meet specific criteria for rare diseases. This particular legislation is enacted under the authority of the Therapeutic Goods Administration, which is a Commonwealth body. The Act designates bortezomib for the treatment of patients with mantle cell lymphoma, thereby identifying Janssen-Cilag Pty Ltd as the sponsor responsible for the therapeutic good. This orphan drug designation is made in accordance with the Therapeutic Goods Regulations 1990, specifically under subregulation 16J(2), aimed at facilitating the development of treatments for conditions that affect a small number of people. The geographic and jurisdictional reach of this Act is national, operating within the framework of Australian law. This Act does not specify any exclusions or exemptions; however, it does establish a clear pathway for the designation of orphan drugs, which can be further detailed or modified through subordinate instruments issued under the authority of the Act.

Key Provisions

The main operative sections of this legislation involve the designation of bortezomib (VELCADE) as an orphan drug for the treatment of mantle cell lymphoma, as detailed in section 16J of the Therapeutic Goods Regulations 1990. This designation, made on 20 August 2014 by Dr Anthony Gill, a Delegate of the Secretary, highlights the specific use of bortezomib in the form of powder for injection. The sponsor of this therapeutic good, Janssen-Cilag Pty Ltd, is clearly identified in the legislation. Under the Therapeutic Goods Act 1989 and its Regulations, the designation of bortezomib as an orphan drug imposes several obligations and requirements on the parties involved. Firstly, the sponsor, Janssen-Cilag Pty Ltd, must ensure that the therapeutic good meets all necessary standards for safety, efficacy, and quality as required by the Therapeutic Goods Administration (TGA). Additionally, the sponsor must provide all necessary information and data to support the orphan drug designation, including clinical trial results and manufacturing details. The legislation also outlines potential consequences for non-compliance with the Therapeutic Goods Act and Regulations. Any breach of the requirements, including failure to meet safety standards or providing false information, may result in significant legal repercussions. Civil penalties can include fines of up to $222,200 for individuals and $1,111,000 for corporations per contravening provision, as stipulated in section 35 of the Act. Furthermore, criminal penalties may apply, with maximum fines of up to $1,111,000 for individuals and $5,555,000 for corporations, alongside potential imprisonment for up to five years for serious or repeated breaches. These penalties underscore the importance of compliance with the regulations governing therapeutic goods in Australia.